Ultragenyx Pharmaceutical Inc. (RARE) — Stock Score Summary

Ultragenyx Pharmaceutical Inc. (RARE) has a MoatMap StockRank of 15/100 based on Quality (22/100), Value (49/100), and Momentum (29/100) factor scores. The current signal is STRONG SELL. Ultragenyx is a commercial-stage biopharmaceutical company focused on rare diseases. Despite having approved products, the company continues to generate significant operating losses and has a high cash burn rate. It does not qualify as a high-ROIC quality compounder and lacks alignment with our active macro themes.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company dedicated to developing and commercializing novel therapies for rare and ultra-rare genetic diseases. The company boasts a diversified pipeline spanning multiple therapeutic areas, with approved products addressing diseases like XLH and GNE myopathy. Ultragenyx's focus on orphan diseases and its integrated approach from research to commercialization gives it a strong competitive position in this high-barrier-to-entry market segment.

Key Financial Metrics

Price$21.78
Market Cap$2.3B
P/E (Forward)23.97
Price/Book-27.88
Return on Invested Capital-44.3%
Gross Margin-28.1%
Operating Margin-102.2%
Revenue Growth-2.2%
Free Cash Flow$-219M

Ultragenyx Pharmaceutical Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Ultragenyx Pharmaceutical Inc.’s (RARE) StockRank?
MoatMap’s StockRank for Ultragenyx Pharmaceutical Inc. (RARE) is 15/100, with a Strong Sell signal. It is a composite of Quality (22), Value (49), and Momentum (29) factor ranks across MoatMap’s 19,000+ stock universe.
Does Ultragenyx Pharmaceutical Inc. have an economic moat?
Ultragenyx Pharmaceutical Inc. (RARE) has a Quality factor score of 22/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Ultragenyx Pharmaceutical Inc. a buy, hold, or sell?
MoatMap’s current signal for Ultragenyx Pharmaceutical Inc. (RARE) is Strong Sell, based on a StockRank of 15/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Ultragenyx Pharmaceutical Inc. in?
Ultragenyx Pharmaceutical Inc. (RARE) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksRARE deep dive reportAI ChampionsHow we score stocksSense-check another stock